LOMON SO
Affiliations: | University of Washington, Seattle, Seattle, WA |
Area:
ImmunologyGoogle:
"LOMON SO"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Xu Y, Poggio M, Jin HY, et al. (2019) Translation control of the immune checkpoint in cancer and its therapeutic targeting. Nature Medicine |
| So L, Lee J, Palafox M, et al. (2016) The 4E-BP-eIF4E axis promotes rapamycin-sensitive growth and proliferation in lymphocytes. Science Signaling. 9: ra57 |
| Vo T, Lee JS, So L, et al. (2015) Abstract IA16: Mechanisms of resistance to mTOR inhibitors in leukemia and lymphoma Molecular Cancer Therapeutics. 14 |
| Limon JJ, So L, Jellbauer S, et al. (2014) mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proceedings of the National Academy of Sciences of the United States of America. 111: E5076-85 |
| Yea SS, So L, Mallya S, et al. (2014) Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. Plos One. 9: e99486 |
| Mallya S, Fitch BA, Lee JS, et al. (2014) Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1. Plos One. 9: e88865 |
| So L, Yea SS, Oak JS, et al. (2013) Selective inhibition of phosphoinositide 3-kinase p110α preserves lymphocyte function. The Journal of Biological Chemistry. 288: 5718-31 |
| So L, Fruman DA. (2012) PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. The Biochemical Journal. 442: 465-81 |
| Janes MR, Limon JJ, So L, et al. (2010) Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nature Medicine. 16: 205-13 |
| Fruman DA, Janes MR, Limon JJ, et al. (2010) Abstract 1798: TORC1/2 inhibitors have more potent anti-leukemic efficacy and are less immunosuppressive than rapamycin Cancer Research. 70: 1798-1798 |